BriaCell Therapeutics Corp Warrant 2021-26.02.26 on BriaCell Therapeutics BCTXW 深 沪
等待开盘 02-11 09:30:00 美东时间
0.0059
-0.002
-26.25%
华盛通- 最 高0.0078
- 今 开0.0044
- 成交量 11.38万股
- 最 低 0.0044
- 昨 收 0.008
- 总市值 4.45万
- 52周最高 0.25
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.0017
- 委 比 -61.29%
- 总股本 753.67万
- 历史最高 7.04
- 量 比 6.73
- 振 幅 42.50%
- 历史最低 0.0017
- 每 手 1
- 风险率 0.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BriaCell Therapeutics Announces Clinical Biomarker Data In Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus An Immune CPI In Metastatic Breast Cancer
Biomarkers identified in BriaCell's Phase 2 study are showing similar and encouraging trends in the ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast cancer (MBC)No new safety or tolerability issues
2025-10-20 19:33
BriaCell to Present Phase 3 Biomarker Data for Bria-IMT in Metastatic Breast Cancer at ESMO 2025
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, will be presenting
2025-10-13 19:34
BriaCell Therapeutics To Present Preclinical Bria-OTS+ Data At SITC Annual Meeting
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to
2025-10-03 19:37
BriaCell Publishes Breakthrough Cancer Immunotherapy Research In JCI Insight Journal
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the
2025-08-26 19:35
BriaCell Announces 1-for-10 Share Consolidation To Maintain Nasdaq Listing, Effective August 25, 2025
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that
2025-08-22 00:02
BriaCell Joins MSK's 2025 Therapeutics Accelerator to Fast-Track Cancer Immunotherapy
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to
2025-08-13 19:36
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer
BriaCell Therapeutics Corp. announced its acceptance into Memorial Sloan Kettering Cancer Center’s 2025 Therapeutics Accelerator program to accelerate the clinical development of its Bria-OTS+ immunotherapy for multiple cancers, including breast and prostate cancer. MSK’s resources will support regulatory and manufacturing efforts, with both parties expressing confidence in the therapy’s potential to advance cancer care.
2025-08-13 11:30
BriaCell Unveils TILsRx Platform Aiming To Supercharge Immune Response Against Hard-To-Treat Cancers
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))), (TSX:BCT) ("BriaCell"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned subsidiary,
2025-07-29 19:34
BriaCell Therapeutics Announces Closing of $15 million Public Offering
BriaCell Therapeutics Corp. has completed a best-efforts public offering of 12 million units, raising $15 million gross proceeds. Each unit includes one common share or a pre-funded warrant and one warrant. The pre-funded warrants are exercisable at $0.001, while the warrants are exercisable at $1.50 per share for five years. The company intends to use the net proceeds for working capital, general corporate purposes, and advancing business object...
2025-07-16 20:05
BriaCell Therapeutics Reports Updated Results From Ongoing Phase 2 Study Of Bria-IMT In Combination With Check Point Inhibitor In Patients With Advanced Metastatic Breast Cancer
Sustained complete resolution of temporal lobe brain metastasis and continued orbital tumor reduction after >18 months of treatment"Eye bulging" metastatic breast cancer patient had failed 8 prior regimens, including
2025-07-10 19:34
